Omics Techniques in Fatty Liver Disease
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Registration Number
- NCT05907408
- Lead Sponsor
- Universidade Federal do Rio de Janeiro
- Brief Summary
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 10
- Metabolic syndrome
- Liver steatosis detected on transient hepatic elastography performed in the last 12 months
- Steatosis with or without fibrosis confirmed histologically in a liver biopsy performed in the last 12 months
- Concurrent liver disease (other than NAFLD)
- Chronic or prolonged use of any potential hepatotoxic drug or substance
- HIV infection
- Cancer (except basal cell carcinoma)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Steatosis, without fibrosis or inflammation 12 months Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation
Steatohepatitis, with fibrosis 12 months Patients with non-alcoholic fatty liver disease presenting with steatosis and degree \>1 of liver fibrosis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Federal University of Rio de Janeiro
🇧🇷Rio de Janeiro, RJ, Brazil